ONCOSYNERGY, INC.
STAMFORD, CT · CIK 0001556747 · Biotech · Private
OS2966, a humanized monoclonal antibody targeting pan-CD29/β1 integrins to prevent secondary neurological damage in traumatic brain injury
oncosynergy.com →- Grants
- $1.0M
- 4 awards
- Sector median: 1
- Raised
- $27M
- 4 Form D · May 2026
- 5 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 2 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $20,006,575 | |
| Private capital raised | Form D · SEC | $200,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel monoclonal antibody for single dose treatment of acute CNS injury | $456,047 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel monoclonal antibody for single dose treatment of acute CNS injury | $200,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel monoclonal antibody for single dose treatment of acute CNS injury | $43,953 | |
| Private capital raised | Form D · SEC | $250,000 | |
| Private capital raised | Form D · SEC | $6,608,832 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3327 | SYNAPTEX, LLC | — | — |
| 3328 | SURFACE BIOADVANCES, INC. | — | — |
| 3329 | LoQus23 Therapeutics | — | — |
| 3330 | ONCOSYNERGY, INC. | — | $27M |
| 3331 | SOLUBLE THERAPEUTICS, INC. | — | — |
| 3332 | SIEYAX, INC | — | — |
| 3333 | Repare Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Anne-Marie CarbonellDirector · Executive Officer
- W. CarbonellDirector · Executive Officer
- Robert DunkleDirector
- Colin FosterDirector
- Amanda HaywardDirector
- Hen ParkDirector
- Allen SalmasiDirector
Patents
- Anti-integrin BETA-1 Antibody Compositions And Methods Of Use Thereofapplication
- Anti-integrin BETA-1 Antibody Compositions And Methods Of Use Thereofgranted
- Anti-integrin BETA-1 Antibody Compositions And Methods Of Use Thereofgranted
- Local Treatment Of Neurofibromasapplication
- Macrocyclic Prodrug Compounds Useful As Therapeuticsapplication
- Anti- Integrin B1 Antibody Compositions And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.